Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3278710.26442/terarkh201890681-88Research ArticleResults of the post-registration clinical study “PARUS” on efficiency and safety assessment of Mydocalm-Richter for local injection therapy of a myofascial trigger zoneDevlikamovaF Ifdevlikamova@mail.ruKSMA - branch of Federal State budgetary educational institution of Higher professional education (FSBEI HPE) «Russian Medical Academy of Continuing Professional Education» Ministry of Health of Russia15062018906818811042020Copyright © 2018, Consilium Medicum2018Aim. The “PARUS” program included investigation of the analgesic, muscle relaxant and sedative effects of Mydocalm-Richter which acts as central muscle relaxant in patients with myofascial pain syndrome, taking into account its registered indication for use - the hypertonus and cross-striated muscle spasm. Materials and methods. Fifty patients with myofascial trigger points, the mean age of 41.67±11.86 years, have been enrolled in the study. All patients had undergone clinical examination that allowed the diagnosis of myofascial pain syndrome. The intensity of pain syndrome was evaluated using the pain visual analogue scales and McGill pain questionnaire. Visualization of area in spasm and evaluation of blood circulation was carried out using the ultrasound scan of target muscle. In order to objectively evaluate any conceivable hypotensive and sedative effects of Mydocalm-Richter we used the orthostatic test, Schulte’s test for attention span and perfor-mance distribution and Munsterberg’s test for attention discrimination and concentration. Results. The analgesic and muscle relaxant effects of Mydocalm-Richter become apparent by day 3 post-injection, and the muscle relaxation effect is reaching its maximum on day 10 post-injection. Cardiovascular function following administration of Mydocalm-Richter was evaluated using the orthostatic test which revealed good orthostatic tolerance. Single injection of tolperisone hydrochloride possessing a central muscle relaxant activity has no sedative effect and does not influence patient response time. The ultrasound examination data demonstrated the improvement and in some cases restoration of blood circulation in the myofascial trigger points. Conclusion. Clinical study “PARUS” conducted in patients with myofascial pain has demonstrated a positive muscle relaxant and analgesic effect of Mydocalm-Richter that resulted in restoration of peripheral circulation in the myofascial trigger pointsconfirmed by ultrasound examination. An important benefit of this drug product is the absence of sedative effect and arterial hypotension.myofascial pain syndromemyofascial trigger pointpainlocal injection therapyMydocalm-Richtersedative effectultrasound examinationtolperisoneмиофасциальный болевой синдроммиофасциальная триггерная зонабольлокальная инъекционная терапияМидокалм-Рихтерседативный эффектультразвуковое исследованиетолперизон[Simons D.G. New views of myofascial trigger points: etiology and diagnosis. Arch Phys Med Rehabil. 2008;89(1):157-9.][Mense S. Muscle Pain: Mechanisms and Clinical Significance. Dtsch Arztebl Int. 2008;105(12):214-9.][Mense S, Gerwin R.D. Muscle Pain: understanding the mechanisms. Springer-Verlag Berlin Heidelberg; 2010. 317 p.][Shah J.P, Thaker N, Heimur J, Aredo J.V, Sikdar S, Gerber L.H. Myofascial Trigger Points Then and Now. A Historical and Scientific Perspectivе. PMR. 2015;7:746-61.][Gerwin R.D, Duranleau D. Ultrasound identification of the myofascial trigger point. Muscle & Nerve. 1997;20:767.][Gerwin R.D, Feinberg L. Ultrasound of the myofascial trigger point. J Musculoskeletal Pain. 1998;6(2)(Suppl):26.][Sikdar S, Shah J.P, Gerber L.H. Novel applications of ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue. Arch Phys Med Rehabil. 2009 Nov;90(11):1829-38.][Ono H, Fukuda H, Kudo Y. Mechanisms of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J Pharmacobiodyn. 1984;7(3):171-6.][Farkas S, Kocsis P, Bielik N. Comparative characterisation of the centrally acting relaxant RGH:5002 and tolperisone and of lidocaine based on their effects on rat spinal cord in vitro. Neurobiology. 1997;5(1):57-8.][Dulin J, Kovacs L, Ramm S, et al. Evaluation of sedative effects of single repeated doses of 50 mg and 150 mg Tolperisone Hydrochloride. Results of prospective, randomized, double - blind, placebo - control trial. Pharmacopsychiatry. 1998;31(4):136-42.][Furuta Y, Yoshikawa A. Reversible adrenergic alpha - receptor blocking action of 2,48-dimethyl-3-piperidino - propiophenone (tolperisone). Jpn J Pharmacol. 1976;26:543-50.][Abranyi I. Study on the effect of 150-mg Mydocalm coated tablets in peripheral vascular diseases and in myotonias of various origin. Hung Med J. 1988;36(2):56-61.][Кукушкин М.Л. Современный взгляд на механизм действия Мидокалма. Российский журнал боли. 2012;(2):15-9.][Хабиров Ф.А., Хабиров Р.А. Мышечная боль. Казань: Книжный дом, 1995. 208 с.][Simons D.G, Trevell J.G, Simons L.S. Myofascial pain and dysfunction. Thetrigger point manual. Williams & Wilknis, 1999. 1038 p.][Снежицкий В.А. Методические аспекты проведения ортостатических проб для оценки состояния вегетативной нервной системы для оценки состояния вегетативной нервной системы и функции синусового узла. Журнал Гродненского государственного медицинского университета. 2006;(1):3-6.]